These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 16989634)

  • 1. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy.
    Singh R; Paterson Y
    Expert Rev Vaccines; 2006 Aug; 5(4):541-52. PubMed ID: 16989634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Listeria-based vaccines for cancer treatment.
    Paterson Y; Maciag PC
    Curr Opin Mol Ther; 2005 Oct; 7(5):454-60. PubMed ID: 16248280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.
    Wallecha A; Carroll KD; Maciag PC; Rivera S; Shahabi V; Paterson Y
    Adv Appl Microbiol; 2009; 66():1-27. PubMed ID: 19203646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.
    Brockstedt DG; Dubensky TW
    Expert Rev Vaccines; 2008 Sep; 7(7):1069-84. PubMed ID: 18767955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine.
    Pan ZK; Ikonomidis G; Pardoll D; Paterson Y
    Cancer Res; 1995 Nov; 55(21):4776-9. PubMed ID: 7585503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector mechanisms.
    Weiskirch LM; Pan ZK; Paterson Y
    Clin Immunol; 2001 Mar; 98(3):346-57. PubMed ID: 11237558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Listeria monocytogenes as novel carrier system for the development of live vaccines.
    Schoen C; Loeffler DI; Frentzen A; Pilgrim S; Goebel W; Stritzker J
    Int J Med Microbiol; 2008 Jan; 298(1-2):45-58. PubMed ID: 17936682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Listeria monocytogenes as an alternative vaccine vector for HIV.
    Mata M; Paterson Y
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):151-62. PubMed ID: 10912619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Listeria monocytogenes and its products as agents for cancer immunotherapy.
    Guirnalda P; Wood L; Paterson Y
    Adv Immunol; 2012; 113():81-118. PubMed ID: 22244580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens.
    Paterson Y; Johnson RS
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S119-34. PubMed ID: 15285711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice.
    Khamisabadi M; Arab S; Motamedi M; Khansari N; Moazzeni SM; Gheflati Z; Hadjati J
    Iran J Immunol; 2008 Mar; 5(1):36-44. PubMed ID: 18319523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live-attenuated Listeria-based immunotherapy.
    Rothman J; Paterson Y
    Expert Rev Vaccines; 2013 May; 12(5):493-504. PubMed ID: 23659298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.
    Paterson Y; Guirnalda PD; Wood LM
    Semin Immunol; 2010 Jun; 22(3):183-9. PubMed ID: 20299242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.
    Wood LM; Paterson Y
    Front Cell Infect Microbiol; 2014; 4():51. PubMed ID: 24860789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic.
    Singh R; Wallecha A
    Hum Vaccin; 2011 May; 7(5):497-505. PubMed ID: 21422819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine.
    Pan ZK; Weiskirch LM; Paterson Y
    Cancer Res; 1999 Oct; 59(20):5264-9. PubMed ID: 10537307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yersinia enterocolitica Yop mutants as oral live carrier vaccines.
    Leibiger R; Niedung K; Geginat G; Heesemann J; Trülzsch K
    Vaccine; 2008 Dec; 26(51):6664-70. PubMed ID: 18822332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary immunotherapy of solid tumors: from tumor-associated antigens to combination treatments.
    Spagnoli GC; Ebrahimi M; Iezzi G; Mengus C; Zajac P
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):184-92. PubMed ID: 20205052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of antitumor immunotherapy mediated by type III secretion system-based live attenuated bacterial vectors.
    Wang Y; Gouëllec AL; Chaker H; Asrih H; Polack B; Toussaint B
    J Immunother; 2012 Apr; 35(3):223-34. PubMed ID: 22421940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.